xRead - September 2022

Wise et al.

Page 464

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

a Specific recommendations for various SLIT preparations and treatment effects are given in section IX.D.4. AC = allergic conjunctivitis; AD = atopic dermatitis; AIT = allergen immunotherapy; AR = allergic rhinitis; ARS = acute rhinosinusitis; BAT = basophil activation test; DSCG = disodium cromoglycate; EC = environmental controls; EoE = eosinophilic esophagitis; ETD = Eustachian tube dysfunction; FDA = Food and Drug Administration; GWAS = genome-wide association study; ILIT = intralymphatic immunotherapy; INCS = intranasal corticosteroids; IND = intranasal decongestants; IPB = ipratropium bromide; LAR = local allergic rhinitis; LTRA = leukotriene receptor antagonist; MQT = Modified Quantitative Testing; NAR = non-allergic rhinitis; NPT = nasal provocation testing; OSA = obstructive sleep apnea; OTE = otitis media with effusion; PAR = perennial allergic rhinitis; PFAS = pollen-food allergy syndrome; QOL = quality of life; RM = rhinitis medicamentosa; SCIT = subcutaneous immunotherapy; SES = socioeconomic status; sIgE = antigen-specific immunoglobulin E; SLIT = sublingual immunotherapy; SPT = skin-prick test; SR = systematic review; tIgE = total immunoglobulin E.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.